T1	Participants 80 130	chemotherapy-induced painful peripheral neuropathy
T2	Participants 217 267	painful chemotherapy-induced peripheral neuropathy
T3	Participants 536 658	231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011
T4	Participants 870 1158	Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.
